Biologics in Europe: Brighter Prospects?
Executive Summary
Biologics have fared far worse in Europe than in the US, both in sales terms and in speed of uptake, according to IMS Global Consulting, despite a similar number of marketed products. The reasons are well known: cost-containment measures, more conservative physician attitudes and complex pricing and reimbursement processes. Yet while absolute growth in the European biologics market is lower than that in the US, the growth of biologics relative to pharmaceuticals is far greater in Europe, which may signal brighter times ahead.